Sign in
Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication In Vitro
Journal article   Open access  Peer reviewed

Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication In Vitro

Patricia A Jorquera, Cynthia Mathew, Jennifer Pickens, Colin Williams, Jasmina M Luczo, Sharon Tamir, Reena Ghildyal and Ralph A Tripp
Journal of virology, Vol.93(4), pp.1-17
15/02/2019
PMCID: PMC6364025
PMID: 30541831
url
Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication In VitroView
Published (Version of record)Free to Read Open

Metrics

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Abstract

A549 Cells Acrylamides - metabolism Acrylamides - pharmacology Active Transport, Cell Nucleus - drug effects Animals Antiviral Agents - pharmacology Apoptosis - drug effects Cell Line Cell Line, Tumor Chlorocebus aethiops Glycoproteins - immunology Humans Hydrazines - metabolism Hydrazines - pharmacology Karyopherins - drug effects Karyopherins - metabolism Receptors, Cytoplasmic and Nuclear - drug effects Receptors, Cytoplasmic and Nuclear - metabolism Respiratory Syncytial Virus Infections - drug therapy Respiratory Syncytial Virus, Human - drug effects Respiratory Syncytial Viruses - drug effects Vero Cells Virus Replication - drug effects

Details